Recommendations
| ShowHide Related Items >><< - 02/07/23
- OneMain Holdings rises 9.9%
- 02/07/23
- OneMain sees low to mid single digit managed receivables growth in 2023
- 02/07/23
- OneMain expects receivables to reach $400M-$500M at year-end 2023
- 02/07/23
- OneMain Holdings raises quarterly dividend 5.3% to $1.00 per share
- 01/27/23 BMO Capital
- World Acceptance price target lowered to $32 from $46 at BMO Capital
- 01/13/23 JMP Securities
- OneMain Holdings price target lowered to $49 from $54 at JMP Securities
- 01/06/23 Barclays
- OneMain Holdings downgraded to Equal Weight from Overweight at Barclays
- 10/28/22 Citi
- OneMain Holdings price target raised to $39 from $38 at Citi
- 02/07/23
- OneMain Holdings reports Q4 adjusted EPS $1.56, consensus $1.51
- 10/26/22
- OneMain Holdings reports Q3 C&I adjusted EPS $1.51, consensus $1.33
- 02/07/23
- Fly Intel: Pre-market Movers
- 10/26/22
- Fly Intel: After-Hours Movers
|
Recommendations
| ShowHide Related Items >><< - 12/13/22 KeyBanc
- nVent Electric downgraded to Sector Weight from Overweight at KeyBanc
- 10/31/22 RBC Capital
- nVent Electric price target raised to $41 from $38 at RBC Capital
- 10/07/22 Loop Capital
- nVent Electric initiated with a Hold at Loop Capital
- 08/01/22 Barclays
- nVent Electric price target raised to $47 from $43 at Barclays
- 02/07/23
- nVent Electric sees Q1 adjusted EPS 56c-58c, consensus 52c
- 02/07/23
- nVent Electric sees FY23 adjusted EPS $2.51-$2.61, consensus $2.49
- 02/07/23
- nVent Electric reports Q4 adjusted EPS 66c, consensus 58c
- 10/28/22
- nVent Electric sees Q4 adjusted EPS 56c-58c, consensus 55c
|
Recommendations
| ShowHide Related Items >><< - $215.71 /
+7.085 (+3.40%) - 02/02/23
- Guardant Health 'pleased' with ruling in Illumina case
- 02/01/23
- Illumina appoints Joydeep Goswami as CFO
- 01/09/23
- Illumina, Nashville Biosciences announce sequencing agreement with Amgen
- 12/05/22
- European Commission says Illumina has to unwind Grail acquisition
- $215.71 /
+7.085 (+3.40%) - 01/27/23 Piper Sandler
- Illumina price target lowered to $290 from $300 at Piper Sandler
- 01/25/23 Argus
- Illumina downgraded to Hold at Argus on valuation, deteriorating outlook
- 01/25/23 Argus
- Illumina downgraded to Hold from Buy at Argus
- 01/17/23 Canaccord
- Illumina price target lowered to $300 from $330 at Canaccord
- $215.71 /
+7.085 (+3.40%) - 02/07/23
- Illumina sees FY23 adjusted EPS $1.25-$1.50, consensus $1.98
- 02/07/23
- Illumina reports Q4 adjusted EPS 14c, consensus 10c
- 02/07/23
- Notable companies reporting after market close
- 11/03/22
- Illumina sees FY22 adjusted EPS $2.35-$2.50, consensus $2.78
- $215.71 /
+7.085 (+3.40%) - 01/11/23
- Illumina to face EU fine of 10% of turnover due to Grail deal, Reuter says
- 01/11/23
- Illumina facing EU fine of 10% turnover over Grail deal, Reuters says
- 10/08/22
- Illumina should be bought before stock drives higher, Barron's says
- 09/29/22
- Illumina launches line of high-end DNA sequences, Statnews reports
- $215.71 /
+7.085 (+3.40%) - 02/07/23
- Fly Intel: After-Hours Movers
- 02/03/23
- Sell these stocks now, proven algorithm says
- 01/11/23
- What You Missed On Wall Street On Wednesday
- 01/05/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- $215.71 /
+7.085 (+3.40%) - 02/07/23
- Illumina options imply 6.4% move in share price post-earnings
- 10/04/22
- Early notable gainers among liquid option names on October 4th
- 09/28/22
- Early notable gainers among liquid option names on September 28th
- 09/06/22
- Early notable gainers among liquid option names on September 6th
|
Recommendations
| ShowHide Related Items >><< - $507.75 /
+22.075 (+4.55%) - 01/12/23
- VolitionRx: Nu.Q Vet Cancer Test available through Idexx Laboratories network
- $507.75 /
+22.075 (+4.55%) - 10/17/22 JPMorgan
- Idexx Laboratories price target lowered to $450 from $525 at JPMorgan
- 08/08/22 Piper Sandler
- Idexx Laboratories price target lowered to $420 from $500 at Piper Sandler
- 08/05/22 Barclays
- Idexx Laboratories price target lowered to $582 from $700 at Barclays
- 07/26/22 Piper Sandler
- Idexx Laboratories price target lowered to $420 from $440 at Piper Sandler
- $507.75 /
+22.075 (+4.55%) - 02/06/23
- Idexx Laboratories sees FY23 comparable EPS up 19%-26%, consensus $9.50
- 02/06/23
- Idexx Laboratories reports Q4 comparable EPS $2.07, consensus $1.94
- 11/01/22
- Idexx Laboratories cuts FY22 EPS view to $7.74-$7.98 from $8.11-$8.35
- 11/01/22
- Idexx Laboratories reports Q3 comparable EPS $2.23, consensus $2.04
- $507.75 /
+22.075 (+4.55%) - 02/06/23
- Fly Intel: Pre-market Movers
- $507.75 /
+22.075 (+4.55%) - 11/01/22
- Early notable gainers among liquid option names on November 1st
|
Recommendations
| ShowHide Related Items >><< - 01/19/23
- Desjardins selects Fiserv to enhance credit card program
- 12/21/22
- Fiserv enters into new contract with CEO Frank Bisignano
- 01/23/23 Barclays
- Fiserv price target lowered to $125 from $128 at Barclays
- 01/09/23 Wells Fargo
- Fiserv downgraded to Underweight from Equal Weight at Wells Fargo
- 12/12/22 Mizuho
- Fiserv price target lowered to $135 from $145 at Mizuho
- 10/28/22 Citi
- Fiserv price target lowered to $115 from $122 at Citi
- 02/07/23
- Fiserv sees FY23 adjusted EPS $7.25-$7.40, consensus $7.29
- 02/07/23
- Fiserv reports Q4 adjusted EPS $1.91, consensus $1.90
- 02/06/23
- Notable companies reporting before tomorrow's open
- 02/06/23
- Notable companies reporting before tomorrow's open
- 02/07/23
- Fly Intel: Pre-market Movers
- 10/27/22
- Fly Intel: Pre-market Movers
- 10/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 08/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/07/23
- Early notable gainers among liquid option names on February 7th
- 12/14/22
- Early notable gainers among liquid option names on December 14th
- 10/10/22
- Fiserv call volume above normal and directionally bullish
- 08/22/22
- Fiserv put volume heavy and directionally bearish
|
Recommendations
| ShowHide Related Items >><< - 02/07/23
- Enphase Energy says plan to begin U.S. manufacturing of microinverters in Q2
- 02/07/23
- Enphase Energy CEO says January activations are holding up
- 02/07/23
- Enphase Energy jumps 11% to $253.91 after Q4 earnings beat
- 02/02/23
- Enphase Energy demonstrates bidirectional EV charger technology
- 02/03/23 Truist
- Enphase Energy price target lowered to $285 from $325 at Truist
- 02/03/23 Janney Montgomery Scott
- Enphase Energy initiated with a Neutral at Janney Montgomery Scott
- 02/01/23 Barclays
- SolarEdge price target lowered to $392 from $396 at Barclays
- 02/01/23 Barclays
- Enphase Energy price target lowered to $251 from $311 at Barclays
- 02/07/23
- Enphase Energy sees Q1 revenue $700M-$740M, consensus $690.46M
- 02/07/23
- Enphase Energy reports Q4 EPS $1.51, consensus $1.24
- 02/07/23
- Notable companies reporting after market close
- 10/25/22
- Enphase Energy sees Q4 revenue $680M-$720M, consensus $660.21M
- 02/07/23
- Fly Intel: After-Hours Movers
- 02/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/30/23
- What You Missed This Week in EVs and Clean Energy
- 12/27/22
- What You Missed This Week in EVs and Clean Energy
- 02/07/23
- Enphase Energy options imply 11.2% move in share price post-earnings
- 02/06/23
- Early notable gainers among liquid option names on February 6th
- 01/30/23
- Enphase Energy call volume above normal and directionally bullish
- 01/25/23
- Unusually active option classes on open January 25th
|
Recommendations
|
Barclays analyst Michael… ShowHide Related Items >><< - 02/07/23
- DuPont increases quarterly dividend 9% to 36c per share
- 11/14/22
- Third Point buys TJX, exits Cenovus Energy in Q3
- 11/10/22
- California AG sues DuPont, 3M over 'toxic forever chemicals'
- 11/08/22
- DuPont approves new $5B share buyback program, plans accelerated share buyback
- 01/17/23 Deutsche Bank
- DuPont downgraded to Hold from Buy at Deutsche Bank
- 01/12/23 KeyBanc
- DuPont downgraded to Sector Weight from Overweight at KeyBanc
- 12/20/22 JPMorgan
- DuPont reinstated with an Overweight at JPMorgan
- 12/15/22 Citi
- DuPont price target raised to $82 from $75 at Citi
- 02/07/23
- DuPont sees FY23 adjusted EPS $3.50-$4.00, consensus $3.84
- 02/07/23
- DuPont sees Q1 adjusted EPS 80c, consensus 89c
- 02/07/23
- DuPont reports Q4 adjusted EPS 89c, consensus 78c
- 11/08/22
- DuPont reports Q3 adjusted EPS 82c, consensus 79c
- 02/07/23
- What You Missed On Wall Street On Tuesday
- 02/07/23
- What You Missed On Wall Street This Morning
- 02/07/23
- Fly Intel: Pre-market Movers
- 11/08/22
- What You Missed On Wall Street On Tuesday
- 02/07/23
- Early notable gainers among liquid option names on February 7th
- 01/19/23
- DuPont de Nemours put volume heavy and directionally bearish
- 11/08/22
- Early notable gainers among liquid option names on November 8th
- 11/08/22
- Unusually active option classes on open November 8th
|
Recommendations
|
Barclays analyst Jeffrey… ShowHide Related Items >><< - $1,720.98 /
+22.435 (+1.32%) - 02/07/23
- Chipotle CEO: Feeling very good about where we are right now
- 02/07/23
- Chipotle sees Q1 comparable restaurant sales growth in high-single digits
- 02/07/23
- Chipotle reports Q4 operating margin 13.6%, up from 8.1% last year
- 01/26/23
- Chipotle launches new hiring campaign
- $1,720.98 /
+22.435 (+1.32%) - 01/23/23 Wells Fargo
- Chipotle initiated with an Overweight at Wells Fargo
- 01/17/23 Morgan Stanley
- Chipotle downgraded to Equal Weight from Overweight at Morgan Stanley
- 01/13/23 Evercore ISI
- Wendy's downgraded to In Line at Evercore, prefers share gainers
- 01/05/23 Barclays
- Chipotle price target lowered to $1,450 from $1,510 at Barclays
- $1,720.98 /
+22.435 (+1.32%) - 02/07/23
- Chipotle reports Q4 adjusted EPS $8.29, consensus $8.90
- 02/07/23
- Notable companies reporting after market close
- 10/25/22
- Chipotle reports Q3 adjusted EPS $9.51, consensus $9.21
- 10/25/22
- Notable companies reporting after market close
- $1,720.98 /
+22.435 (+1.32%) - 01/12/23
- Conagra doesn't see need for 'big' price hikes in 2023, WSJ says
- 01/11/23
- Subway looks into sale that could value company at over $10B, WSJ says
- 12/30/22
- Restaurant coalition sues to stop California fast-food wage law, WSJ says
- 12/01/22
- Twitter offers advertisers big incentives to boost spending, WSJ reports
- $1,720.98 /
+22.435 (+1.32%) - 02/07/23
- Fly Intel: After-Hours Movers
- 01/24/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/17/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/07/22
- #SocialStocks: EU rules against Meta, despite attempts to settle
- $1,720.98 /
+22.435 (+1.32%) - 02/07/23
- Chipotle options imply 5.5% move in share price post-earnings
- 10/25/22
- Chipotle options imply 6.3% move in share price post-earnings
|
Earnings
| ShowHide Related Items >><< - 02/01/23
- Euronet's platform to enhance prepaid card issuing services for SOLFIN
- 12/15/22
- Euronet launches refreshed brand strategy, new logo, mission statement
- 12/13/22
- Euronet announces Ren Payments Platform selected by BNC
- 12/08/22
- Euronet appoints Torres to board of directors
- 01/23/23 Citi
- Euronet downgraded to Neutral from Buy at Citi
- 01/20/23 Truist
- Euronet price target raised to $135 from $100 at Truist
- 01/12/23 DA Davidson
- DA Davidson expects material FX headwinds for Euronet to diminish
- 01/05/23 Wolfe Research
- Euronet downgraded to Underperform from Peer Perform at Wolfe Research
|
Recommendations
| ShowHide Related Items >><< - 02/02/23
- Managed care stocks pressured after CMS' preliminary Medicare Advantage rates
- 01/23/23
- Centene completes divestiture of Magellan Specialty Health to Evolent Health
- 01/03/23
- Centene's Health Net selected for new medi-cal direct contracts
- 12/16/22
- Centene announces $2B increase to stock repurchase program
- 01/31/23 JPMorgan
- Medicare Advantage final rule more favorable than feared, says JPMorgan
- 12/23/22 Wells Fargo
- Humana keeps TRICARE East, Centene loses West region, says Wells Fargo
- 12/23/22 Credit Suisse
- TRICARE contract a win for Humana, loss for Centene, says Credit Suisse
- 12/14/22 Argus
- Centene price target raised to $99 from $95 at Argus
- 02/07/23
- Centene backs FY23 adjusted EPS view $6.25-$6.40, consensus $6.36
- 02/07/23
- Centene reports Q4 EPS 86c, consensus 85c
- 02/06/23
- Notable companies reporting before tomorrow's open
- 02/06/23
- Notable companies reporting before tomorrow's open
- 11/29/22
- Managed care company returns will be tough to keep replicating, WSJ says
- 09/23/22
- Nebraska picks two current, one new Medicaid health plan provider, OWH reports
- 09/23/22
- UnitedHealth, Molina, Centene win Medicaid contracts in Nebraska, Bloomberg says
- 08/18/22
- White House plans for end of COVID-19 vaccine coverage, WSJ reports
- 01/03/23
- What You Missed On Wall Street On Tuesday
- 01/03/23
- What You Missed On Wall Street This Morning
- 12/16/22
- What You Missed On Wall Street On Friday
- 12/16/22
- What You Missed On Wall Street This Morning
- 01/17/23
- Centene call volume above normal and directionally bullish
- 01/09/23
- Centene put volume heavy and directionally bearish
- 12/22/22
- Early notable gainers among liquid option names on December 22nd
- 11/21/22
- Centene put volume heavy and directionally bearish
|